Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed financial performance with a net loss and decreased revenues. Despite some positive indicators like operational improvements and increased HA manufacturing demand, challenges such as increased SG&A expenses, supply chain issues, and litigation costs persist. The Q&A section did not provide sufficient clarity on key issues, and the absence of a share repurchase program further dampens sentiment. While there is optimism around future growth and cash flow improvements, the current financial struggles and uncertainties result in a negative outlook for the stock price.
Revenue $35.2 million, a decrease of 2% year-over-year from $35.7 million. The decrease was primarily due to a $1.5 million decrease in CDMO revenues, offset by a $1 million increase in HA manufacturing revenues due to increased demand.
Gross Profit $9.8 million, a decrease of $2 million from $11.9 million year-over-year. The decline was due to a $3 million decrease in CDMO gross profit, offset by a $1 million increase in HA manufacturing gross profit.
SG&A Expenses $10.1 million, an increase from $9.8 million year-over-year. Excluding stock-based compensation, SG&A decreased by $0.7 million due to lower finance and accounting consulting, but included $2.2 million in litigation expenses.
Net Loss $14.8 million or $0.47 loss per diluted share, compared to net income of $15.6 million or $0.42 income per diluted share last year. The prior year included a one-time favorable $21 million non-cash fair market value adjustment.
Adjusted EBITDA $5.7 million, a decrease of $0.7 million from $6.4 million year-over-year. The decrease was primarily due to the decrease in gross profit, exclusive of inventory and equipment write-off.
Revenue (Nine Months) $92.4 million, an increase of 2% year-over-year from $90.4 million. The increase was due to a $3 million increase in HA manufacturing demand, offset by a decrease in CDMO revenues.
Gross Profit (Nine Months) $26.3 million, an increase of $1.7 million from $24.6 million year-over-year. The improvement was primarily due to an increase in HA manufacturing gross profit.
SG&A Expenses (Nine Months) $35.1 million, an increase from $28.2 million year-over-year. Excluding a $3.8 million increase in stock-based compensation, SG&A is up $3.1 million due to various legacy legal matters.
Net Loss (Nine Months) $37.6 million or $1.24 loss per diluted share, compared to net income of $19.1 million or $0.52 income per diluted share last year. The prior year included a one-time favorable $41.9 million non-cash fair market value adjustment.
Adjusted EBITDA (Nine Months) $10.4 million, a $0.6 million increase from $9.8 million year-over-year, primarily due to the increase in gross profit.
New Product Agreements: Lifecore signed a new agreement with Nirsum Laboratories to provide CDMO services for clinical development of NRS-033, a treatment for opioid and alcohol use disorders.
New Customer Acquisition: Lifecore added six new customers in the first nine months of fiscal 2025, including a significant agreement with Humanetics for their BIO 300 program.
Market Expansion: Lifecore is expanding its business with a large multinational partner, which is expected to significantly increase volume demand by 2027.
Operational Efficiencies: Lifecore has implemented state-of-the-art technologies and improved coordination between supply chain and operations, resulting in better production scheduling and increased yields.
Cost Reduction Initiatives: The company has reduced operational expenses by hiring in-house talent and eliminating unnecessary consulting relationships.
Strategic Growth Focus: Lifecore aims for a 12% revenue CAGR and over 25% EBITDA margins by maximizing existing customer business and advancing late-stage pipeline programs towards commercialization.
Earnings Expectations: Lifecore Biomedical, Inc. missed earnings expectations with a reported EPS of $-0.19, compared to expectations of $-0.14.
Revenue Decrease: Revenues for Q3 2025 decreased by 2% to $35.2 million, primarily due to a $1.5 million decrease in CDMO revenues.
Litigation Expenses: SG&A expenses included $2.2 million related to litigation expenses from an activist investor matter and a securities class action lawsuit.
Net Loss: The company recorded a net loss of $14.8 million for Q3 2025, compared to a net income of $15.6 million in the same period last year.
Regulatory Approval Risks: Ten late-stage pipeline programs are poised for potential FDA approval by 2028, but there is no guarantee that all will reach commercialization.
Supply Chain Challenges: The decrease in CDMO revenues was attributed to the completion of discrete development revenue and timing of customer projects, indicating potential supply chain challenges.
Operational Efficiency: While improvements in operational efficiency were noted, the company is still facing challenges in managing production schedules and workforce without compromising customer service.
Increased SG&A Expenses: SG&A expenses increased significantly due to legacy legal matters and costs associated with financial restatement, indicating ongoing financial management challenges.
Revenue Growth Strategy: Lifecore aims for a 12% revenue CAGR and increasing EBITDA margins to over 25% over the next few years.
Customer Expansion: The company is expanding its business with a large multinational partner, expected to deliver significant volume demand by 2027.
Pipeline Advancement: Ten late-stage pipeline programs are poised for potential FDA approval and commercialization by 2028.
New Business Development: Lifecore has added six new customers in the first nine months of fiscal 2025, including agreements with Nirsum Laboratories and Humanetics.
Operational Efficiency: The company is implementing measures to reduce operational expenses and improve productivity without compromising quality.
Revenue Guidance: Lifecore expects revenue to be approximately $126.5 million to $130 million for fiscal 2025.
Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA to be in the range of $19 million to $21 million for fiscal 2025.
Share Repurchase Program: None
The earnings call summary indicates strong financial metrics with improved net loss and EBITDA, alongside strategic advancements like new commercial agreements and operational enhancements. The Q&A reveals positive sentiment from analysts, especially regarding cost reductions and revenue upticks. Despite some unclear responses, the overall guidance and strategic plans, including a commercial win and collaboration opportunities, suggest positive momentum. Thus, the stock is likely to experience a positive movement in the short term.
The earnings call summary presents mixed signals: a slight revenue increase, but a significant net loss and decreased EBITDA. The Q&A highlights potential growth in aseptic manufacturing and a new GLP-1 agreement, but lacks clarity on specifics. Despite strategic partnerships and future growth potential, current financials and unclear guidance temper expectations, leading to a neutral sentiment.
The earnings call reveals a mixed financial performance with a net loss and decreased revenues. Despite some positive indicators like operational improvements and increased HA manufacturing demand, challenges such as increased SG&A expenses, supply chain issues, and litigation costs persist. The Q&A section did not provide sufficient clarity on key issues, and the absence of a share repurchase program further dampens sentiment. While there is optimism around future growth and cash flow improvements, the current financial struggles and uncertainties result in a negative outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
